FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2117804889> ?p ?o ?g. }

• W2117804889 endingPage "1434" @default.
• W2117804889 startingPage "1424" @default.
• W2117804889 abstract "Objectives To assess the cost-effectiveness of the new QuantiFERON-TB Gold In-Tube (QFT-G) [Cellestis; Carnegie, VIC, Australia] assay for screening and treating of persons who have had close contact with tuberculosis (TB) patients and are suspected of having latent tuberculosis infection (LTBI) [hereafter called close-contacts] in Germany. Methods The health and economic outcomes of isoniazid treatment of 20-year-old close-contacts were compared in a Markov model over a period of 20 years, using two different cutoff values for the tuberculin skin test (TST), the QFT-G assay alone, or the QFT-G assay as a confirmatory test for the TST results. Results QFT-G assay-based treatment led to cost savings of $542.9 and 3.8 life-days gained per LTBI case. TST-based treatment at a 10-mm induration size cutoff gained $177.4 and 2.0 life-days gained per test-positive contact. When the cutoff induration size for the TST was reduced to 5 mm, the incremental cost-effectiveness ratio fell below the willingness-to-pay threshold ($30,170 per life-years gained) but resulted in unnecessary treatment of 77% of contacts owing to false-positive TST results. Combination with the 5-mm induration size TST cutoff value compared to the results of the QFT-G assay alone reduced the total costs per 1,000 contacts by 1.8% to $222,869. The number treated to prevent 1 TB case was 22 for the two QFT-G assay-based procedures, 40 for the TST at a cutoff induration size of 10 mm, and 96 for the TST at a cutoff induration size of 5 mm. When the sensitivity rates of the TST and the QFT-G assay were compounded, the QFT-G assay strategy alone was slightly less costly (0.6%) than the two-step approach. Conclusions Using the QFT-G assay, but especially combining the QFT-G assay following the TST screening of close-contacts at a cutoff induration size of 5 mm before LTBI treatment is highly cost-effective in reducing the disease burden of TB. To assess the cost-effectiveness of the new QuantiFERON-TB Gold In-Tube (QFT-G) [Cellestis; Carnegie, VIC, Australia] assay for screening and treating of persons who have had close contact with tuberculosis (TB) patients and are suspected of having latent tuberculosis infection (LTBI) [hereafter called close-contacts] in Germany. The health and economic outcomes of isoniazid treatment of 20-year-old close-contacts were compared in a Markov model over a period of 20 years, using two different cutoff values for the tuberculin skin test (TST), the QFT-G assay alone, or the QFT-G assay as a confirmatory test for the TST results. QFT-G assay-based treatment led to cost savings of $542.9 and 3.8 life-days gained per LTBI case. TST-based treatment at a 10-mm induration size cutoff gained $177.4 and 2.0 life-days gained per test-positive contact. When the cutoff induration size for the TST was reduced to 5 mm, the incremental cost-effectiveness ratio fell below the willingness-to-pay threshold ($30,170 per life-years gained) but resulted in unnecessary treatment of 77% of contacts owing to false-positive TST results. Combination with the 5-mm induration size TST cutoff value compared to the results of the QFT-G assay alone reduced the total costs per 1,000 contacts by 1.8% to $222,869. The number treated to prevent 1 TB case was 22 for the two QFT-G assay-based procedures, 40 for the TST at a cutoff induration size of 10 mm, and 96 for the TST at a cutoff induration size of 5 mm. When the sensitivity rates of the TST and the QFT-G assay were compounded, the QFT-G assay strategy alone was slightly less costly (0.6%) than the two-step approach. Using the QFT-G assay, but especially combining the QFT-G assay following the TST screening of close-contacts at a cutoff induration size of 5 mm before LTBI treatment is highly cost-effective in reducing the disease burden of TB." @default.
• W2117804889 created "2016-06-24" @default.
• W2117804889 creator A5004238053 @default.
• W2117804889 creator A5053101542 @default.
• W2117804889 creator A5069578858 @default.
• W2117804889 date "2007-05-01" @default.
• W2117804889 modified "2023-10-04" @default.
• W2117804889 title "Cost-effectiveness of Interferon-γ Release Assay Screening for Latent Tuberculosis Infection Treatment in Germany" @default.
• W2117804889 cites W1608173047 @default.
• W2117804889 cites W1893676832 @default.
• W2117804889 cites W1983077806 @default.
• W2117804889 cites W2043951092 @default.
• W2117804889 cites W2060976609 @default.
• W2117804889 cites W2064727915 @default.
• W2117804889 cites W2076728105 @default.
• W2117804889 cites W2091351254 @default.
• W2117804889 cites W2100136451 @default.
• W2117804889 cites W2102650083 @default.
• W2117804889 cites W2102777134 @default.
• W2117804889 cites W2117518632 @default.
• W2117804889 cites W2132180171 @default.
• W2117804889 cites W2134823509 @default.
• W2117804889 cites W2140909669 @default.
• W2117804889 cites W2156389983 @default.
• W2117804889 cites W2164487732 @default.
• W2117804889 cites W2165801752 @default.
• W2117804889 cites W2169344045 @default.
• W2117804889 doi "https://doi.org/10.1378/chest.06-2728" @default.
• W2117804889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17494792" @default.
• W2117804889 hasPublicationYear "2007" @default.
• W2117804889 type Work @default.
• W2117804889 sameAs 2117804889 @default.
• W2117804889 citedByCount "77" @default.
• W2117804889 countsByYear W21178048892012 @default.
• W2117804889 countsByYear W21178048892013 @default.
• W2117804889 countsByYear W21178048892014 @default.
• W2117804889 countsByYear W21178048892015 @default.
• W2117804889 countsByYear W21178048892016 @default.
• W2117804889 countsByYear W21178048892017 @default.
• W2117804889 countsByYear W21178048892018 @default.
• W2117804889 countsByYear W21178048892019 @default.
• W2117804889 countsByYear W21178048892020 @default.
• W2117804889 countsByYear W21178048892022 @default.
• W2117804889 countsByYear W21178048892023 @default.
• W2117804889 crossrefType "journal-article" @default.
• W2117804889 hasAuthorship W2117804889A5004238053 @default.
• W2117804889 hasAuthorship W2117804889A5053101542 @default.
• W2117804889 hasAuthorship W2117804889A5069578858 @default.
• W2117804889 hasConcept C112930515 @default.
• W2117804889 hasConcept C121332964 @default.
• W2117804889 hasConcept C126322002 @default.
• W2117804889 hasConcept C141071460 @default.
• W2117804889 hasConcept C142724271 @default.
• W2117804889 hasConcept C2776247216 @default.
• W2117804889 hasConcept C2776763545 @default.
• W2117804889 hasConcept C2776967927 @default.
• W2117804889 hasConcept C2777975735 @default.
• W2117804889 hasConcept C2778217198 @default.
• W2117804889 hasConcept C2778690821 @default.
• W2117804889 hasConcept C2779806340 @default.
• W2117804889 hasConcept C2780277586 @default.
• W2117804889 hasConcept C2780841837 @default.
• W2117804889 hasConcept C2781069245 @default.
• W2117804889 hasConcept C2992250361 @default.
• W2117804889 hasConcept C3019080777 @default.
• W2117804889 hasConcept C3020380090 @default.
• W2117804889 hasConcept C62520636 @default.
• W2117804889 hasConcept C71924100 @default.
• W2117804889 hasConceptScore W2117804889C112930515 @default.
• W2117804889 hasConceptScore W2117804889C121332964 @default.
• W2117804889 hasConceptScore W2117804889C126322002 @default.
• W2117804889 hasConceptScore W2117804889C141071460 @default.
• W2117804889 hasConceptScore W2117804889C142724271 @default.
• W2117804889 hasConceptScore W2117804889C2776247216 @default.
• W2117804889 hasConceptScore W2117804889C2776763545 @default.
• W2117804889 hasConceptScore W2117804889C2776967927 @default.
• W2117804889 hasConceptScore W2117804889C2777975735 @default.
• W2117804889 hasConceptScore W2117804889C2778217198 @default.
• W2117804889 hasConceptScore W2117804889C2778690821 @default.
• W2117804889 hasConceptScore W2117804889C2779806340 @default.
• W2117804889 hasConceptScore W2117804889C2780277586 @default.
• W2117804889 hasConceptScore W2117804889C2780841837 @default.
• W2117804889 hasConceptScore W2117804889C2781069245 @default.
• W2117804889 hasConceptScore W2117804889C2992250361 @default.
• W2117804889 hasConceptScore W2117804889C3019080777 @default.
• W2117804889 hasConceptScore W2117804889C3020380090 @default.
• W2117804889 hasConceptScore W2117804889C62520636 @default.
• W2117804889 hasConceptScore W2117804889C71924100 @default.
• W2117804889 hasIssue "5" @default.
• W2117804889 hasLocation W21178048891 @default.
• W2117804889 hasLocation W21178048892 @default.
• W2117804889 hasOpenAccess W2117804889 @default.
• W2117804889 hasPrimaryLocation W21178048891 @default.
• W2117804889 hasRelatedWork W1995459579 @default.
• W2117804889 hasRelatedWork W2067756856 @default.
• W2117804889 hasRelatedWork W2117804889 @default.
• W2117804889 hasRelatedWork W2125709734 @default.
• W2117804889 hasRelatedWork W2153081964 @default.

• next